Because inhibition of RIP3 kinase activity shows beneficial effects in certain pathological settings but cancer therapies may require RIP3 activity to induce necroptosis, regulation of kinase activity should be considered depending on the drugs used as therapeutic targets. Here, RIPK3 is linked to cancer.